Development of epidermal growth factor receptor targeted therapy in pancreatic cancer
1Department of Endocrinology, China-Japan Union Hospital of Jilin University, Changchun, China.
Abstract:
The epidermal growth factor receptor (EGFR) family is a series of important cancer therapeutic targets involved in cancer biology. These genes play an important role in tumor biological characteristics including angiogenesis, cell survival, invasion and glucose metabolism. In recent years, progress has been achieved on the cellular and molecular biological characteristics of EGFR and its role in cancer development based on the study of tumor specimens and experimental animal model. EGFR (HER1/ErbB) is overexpressed in over sixty percent of triple-negative breast cancers and occurs in pancreatic, bladder, lung and head-and-neck cancers. Up to now, EGFR inhibitors have been applied in various types of cancer, such as lung cancer, breast cancer, bladder cancer and head and neck cancers etc., in which the combination of EGFR inhibitors plus chemotherapeutic agents is now seen as the standard of cure for advanced/metastatic pancreatic cancer. For these reasons, EGFR inhibitors and their therapeutic effect for pancreatic cancer is becoming the focus in laboratory and clinical research. In this paper, research progress of the development of epidermal growth factor receptor targeted therapy in pancreatic cancer is introduced.
Insights
Epidermal growth factor receptor (EGFR) targeted therapy shows promise for pancreatic cancer. Research highlights EGFR inhibitors
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Epidermal growth factor receptor (EGFR) family is crucial in cancer biology, influencing angiogenesis, cell survival, invasion, and metabolism.
- EGFR is overexpressed in various cancers, including triple-negative breast, pancreatic, lung, and head-and-neck cancers.
- EGFR inhibitors are established treatments for several cancers, with combined therapies standard for advanced pancreatic cancer.
Purpose of the Study:
- To review the research progress of epidermal growth factor receptor targeted therapy specifically in pancreatic cancer.
- To highlight the therapeutic potential and ongoing research into EGFR inhibitors for pancreatic cancer treatment.
Main Methods:
- Review of cellular and molecular biological characteristics of EGFR.
- Analysis of studies on tumor specimens and experimental animal models.
- Examination of clinical research and therapeutic applications of EGFR inhibitors.
Main Results:
- EGFR plays a significant role in tumor progression across multiple cancer types.
- EGFR inhibitors have demonstrated efficacy in various cancers, including pancreatic cancer.
- Combination therapy with EGFR inhibitors and chemotherapy is a standard for advanced pancreatic cancer.
Conclusions:
- EGFR targeted therapy is a key focus in pancreatic cancer research.
- Further investigation into EGFR inhibitors is warranted for optimizing pancreatic cancer treatment.
- EGFR inhibitors represent a significant advancement in targeted cancer therapy.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:28Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
01:29Factors Influencing Microbial Growth: pH
01:27Factors Influencing Microbial Growth: Temperature
01:28Factors Influencing Microbial Growth: Osmolarity